BLOG

Fierce-Pharma

Valneva’s not too late in COVID-19 as analysts eye $1.1B in 2022 vaccine sales

Valneva has yet to successfully usher its inactivated COVID-19 vaccine across the regulatory finish line, but analysts still see reason to bet on the French vaccine specialist.